Indazole and azaindazole Btk inhibitors

Patent metadata

Field	Value
Publication number	US-10246457-B2
Application number	US-201615564352-A
Country	US
Kind code	B2
Filing date	Apr 4, 2016
Priority date	Apr 8, 2015
Publication date	Apr 2, 2019
Grant date	Apr 2, 2019

Abstract

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , R 1 , R 7 , R 8 and R 9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

First claim

The invention claimed is:

1. A compound of Formula (I)

wherein:
X 1 is N or C(H);
X 2 is N or C(R 6 );
R 1 is H, C 1-3 akyl, or —CH 2 —R 1a , wherein R 1a is phenyl or pyridyl;
R 6 is H or C 1-3 alkyl;
R 7 is:
(a.) a group of the formula —C(O)N(R 7a )(R 7b ), wherein R 7a and R 7b are independently H or C 1-3 alkyl; or alternatively, R 7a and R 7b together with the N to which they are attached form a 5- to 6-membered heterocyclyl optionally containing 1 additional heteroatom selected from N or O;
(b.) Cy, wherein Cy is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 N ring atoms; wherein Cy is unsubstituted or substituted by 1 to 2 R c substituents selected from:
(i.) C 1-4 alkyl,
(ii.) a group of the formula —C(R 7d ) 2 CO 2 H,
wherein R 7d is H or C 1-3 alkyl;

(iii.) —CH 2 CH 2 OCH 3 ; or
(iv.) tetrahydropyranyl;
or alternatively, two R c substituents, together with the atoms to which they are attached form a 5- to 6-membered heterocyclyl containing 1 N ring atom;

(c.) —C(O)OH;
(d.) H;
(e.) C 1-3 alkyl; or
(f.) C 1-3 fluoroalkyl;

R 8 is H, C 1-3 alkyl or C 1-3 hydroxyalkyl;
R 9 is:

 or

a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X 2 is C(R 6 ).

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X 1 and X 2 are both C(H).

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is H.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 7 is
(a.) a group of the formula —C(O)N(R 7a )(R 7b ), wherein R 7a and R 7b are independently H or methyl; or alternatively, R 7a and R 7b together with the N to which they are attached form a morpholinyl ring;
(b.) Cy,wherein Cy is phenyl, pyrazolyl, or pyridinyl; wherein Cy is unsubstituted or substituted by 1 to 2 R c substituents selected from:
(i.) C 1-4 alkyl,
(ii.) a group of the formula —C(R 7d ) 2 CO 2 H,
wherein R 7d is H or methyl;

(iii.) —CH 2 CH 2 OCH 3 ; or
(iv.) tetrahydropyranyl;

(c.) —C(O)OH;
(d.) H;
(e.) methyl; or
(f.) trifluoromethyl.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 8 is hydroxymethyl or methyl.

7. A compound which is:
3-amino-5-[3-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-2-(hydroxymethyl)phenyl]-1H-indazole-7-carboxylic acid,
2-[3-(3-amino-6-methyl-1H-indazol-5-yl)-2-(hydroxymethyl)phenyl]-6-tert-butyl-8-fluorophthalazin-1(2H)-one,
3-amino-5-[3-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-2-(hydroxymethyl)phenyl]-1H-indazole-7-carboxamide,
2-{3-[3-amino-7-(trifluoromethyl)-1H-indazol-5-yl]-2-(hydroxymethyl)phenyl}-6-tert-butyl-8-fluorophthalazin-1(2H)-one,
3-amino-5-[3-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-2-(hydroxymethyl)phenyl]-1-methyl-1H-indazole-7-carboxamide,
2-[3-{3-amino-7-[1-(1-methylethyl)-1H-pyrazol-4-yl]-1H-indazol-5-yl}-2-(hydroxymethyl)phenyl]-6-tert-butyl-8-fluorophthalazin-1(2H)-one,
3-amino-5-(3-{[(4-tert-butyl-2-fluorophenyl)carbonyl]amino}-2-methylphenyl)-1H-indazole-7-carboxamide,
3-amino-5-[3-({[2-fluoro-4-(2,2,2-trifluoro-1,1-dimethylethyl)phenyl]carbonyl}amino)-2-methylphenyl]-1H-indazole-7-carboxamide,
2-{3-[3-amino-7-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl]-2-(hydroxymethyl)phenyl}-6-tert-butyl-8-fluorophthalazin-1(2H)-one,
2[3-(3-3-(3-amino-7-pyridin-3-yl-1H-indazol-5-yl)-2-(hydroxymethyl)phenyl]-6-tert-butyl-8-fluorophthalazin-1(2H)-one,
3-amino-5[3-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-2-(hydroxymethyl)phenyl]-N-methyl-1H-indazole-7-carboxamide,
2-{3[3-amino-1-(pyridin-4-ylmethyl)-1H-indazol-5-yl]-2-(hydroxymethyl)phenyl}-6-tert-butyl-8-fluorophthalazin-1(2H)-one,
N-{3[3-amino-7-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl]-2-methylphenyl}-4-tert-butylbenzamide,
2-{3-[3-amino-7-(morpholin-4-ylcarbonyl)-1H-indazol-5-yl]-2-(hydroxymethyl)phenyl}-6-tert-butyl-8-fluorophthalazin-1(2H)-one,
N-{3-[3-amino-7-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl]-2-methylphenyl1}-4-tert-butyl-2-fluorobenzamide,
3-amino-5-[3-(6-tert-butyl-8-fluoro-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)-2-(hydroxymethyl)phenyl]-1H-indazole-7-carboxamide,
2-[3-{3-amino-7-[-1-(1-methylethyl)-1H-pyrazol-3-yl]-1H-indazol-5-yl}-2-(hydroxymethyl)phenyl]-6-tert-butyl-8-fluorophthalazin-1(2H)-one,
N-{3-[3-amino-7-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl]-2-(hydroxymethyl)phenyl}-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide,
2-[3-(3-amino-7-phenyl-1H-indazol-5-yl)-2-(hydroxymethyl)phenyl]-6-tert-butyl-8-fluorophthalazin-1(2H)-one,
2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridin-5-yl)-2-(hydroxymethyl)phenyl]-6-tert-butyl-8-fluorophthalazin-1(2H)-one,
2-[3-(3-amino-1H-pyrazolo[3,4-c]pyridin-5-yl)-2-(hydroxymethyl)phenyl]-6-tert-butyl-8-fluorophthalazin-1(2H)-one,
2-(3-(3-amino-7-(pyridin-2-yl)-1H-indazol-5-yl)-2-(hydroxymethyl)phenyl)-6-(tert-butyl)-8-fluorophthalazin-1(2H)-one,
2-(4-(3-amino-5-(3-(6-(tert-butyl)-8-fluoro-1-oxophthalazin-2(1H)-yl)-2-(hydroxymethyl)phenyl)-1H-indazol-7-yl)-1H-pyrazol-1-yl)acetic acid,
2-(4-(3-amino-5-(3-(6-(tert-butyl)-8-fluoro-1-oxophthalazin-2(1H)-yl)-2-(hydroxymethyl)phenyl)-1H-indazol-7-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid,
2-(3-(3-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-indazol-5-yl)-2-(hydroxymethyl)phenyl)-6-(tert-butyl)-8-fluorophthalazin-1(2H)-one,
2-(3-(3-amino-7-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-1H-indazol-5-yl)-2-(hydroxymethyl)phenyl)-6-(tert-butyl)-8-fluorophthalazin-1(2H)-one,
2-(3-(3-amino-7-(1,3-dimethyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-2-(hydroxymethyl)phenyl)-6-(tert-butyl)-8-fluorophthalazin-1(2H)-one,
2-(3-(3-amino-7-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-1H-indazol-5-yl)-2-(hydroxymethyl)phenyl)-6-(tert-butyl)-8-fluorophthalazin-1(2H)-one,

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Assignees

• Merck Sharp & Dohme

Inventors

• Siu Tony
• Altman Michael D
• Andresen Brian M
• Liu Jian
• Kozlowski Joseph
• Boga Sobhana Babu
• Yu Younong
• Anand Rajan
• Cai Jiaqiang
• Wang Dahai
• Liu Shilan

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07D403/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D409/14

  containing three or more hetero rings · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title

• C07D401/10

  linked by a carbon chain containing aromatic rings · CPC title